The IBD interactome: an integrated view of aetiology, pathogenesis and therapy

被引:300
|
作者
de Souza, Heitor S. P. [1 ,2 ]
Fiocchi, Claudio [3 ]
Iliopoulos, Dimitrios [4 ]
机构
[1] Univ Fed Rio de Janeiro, Dept Gastroenterol, BR-21941913 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Multidisciplinary Res Lab, BR-21941913 Rio De Janeiro, Brazil
[3] Cleveland Clin, Digest Dis & Surg Inst, Dept Gastroenterol & Hepatol, Dept Pathobiol,Lerner Res Inst, Cleveland, OH 44195 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Syst Biomed Vatche & Tamar Manoukian, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA
关键词
INFLAMMATORY-BOWEL-DISEASE; CYTOSCAPE PLUG-IN; ULCERATIVE-COLITIS; CROHNS-DISEASE; GENE-EXPRESSION; GUT MICROBIOTA; MOLECULAR NETWORKS; COMPLEX DISEASES; SYSTEMS BIOLOGY; DOUBLE-BLIND;
D O I
10.1038/nrgastro.2017.110
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Crohn's disease and ulcerative colitis are prototypical complex diseases characterized by chronic and heterogeneous manifestations, induced by interacting environmental, genomic, microbial and immunological factors. These interactions result in an overwhelming complexity that cannot be tackled by studying the totality of each pathological component (an '-ome') in isolation without consideration of the interaction among all relevant - omes that yield an overall 'network effect'. The outcome of this effect is the 'IBD interactome', defined as a disease network in which dysregulation of individual - omes causes intestinal inflammation mediated by dysfunctional molecular modules. To define the IBD interactome, new concepts and tools are needed to implement a systems approach; an unbiased data-driven integration strategy that reveals key players of the system, pinpoints the central drivers of inflammation and enables development of targeted therapies. Powerful bioinformatics tools able to query and integrate multiple - omes are available, enabling the integration of genomic, epigenomic, transcriptomic, proteomic, metabolomic and microbiome information to build a comprehensive molecular map of IBD. This approach will enable identification of IBD molecular subtypes, correlations with clinical phenotypes and elucidation of the central hubs of the IBD interactome that will aid discovery of compounds that can specifically target the hubs that control the disease.
引用
收藏
页码:739 / +
页数:11
相关论文
共 50 条
  • [21] Current recommendations on the role of diet in the aetiology and management of IBD
    Gerasimidis, Konstantinos
    Godny, Lihi
    Sigall-Boneh, Rotem
    Svolos, Vaios
    Wall, Catherine
    Halmos, Emma
    FRONTLINE GASTROENTEROLOGY, 2022, 13 (02) : 160 - 167
  • [22] Aetiology and Pathogenesis of IUGR
    Sankaran, Srividhya
    Kyle, Phillipa M.
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2009, 23 (06) : 765 - 777
  • [23] Optimization of conventional therapy in patients with IBD
    Taylor, Kirstin M.
    Irving, Peter M.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (11) : 646 - 656
  • [24] Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility
    Ye, Byong Duk
    McGovern, Dermot P. B.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (10) : 1091 - 1107
  • [26] IBD - PROGRESS IN PATHOGENESIS
    FIOCCHI, C
    STRONG, SA
    WEST, GA
    KLEIN, JS
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1993, 7 (02): : 110 - 114
  • [27] Insights into IBD pathogenesis
    Targan S.R.
    Shih D.Q.
    Current Gastroenterology Reports, 2009, 11 (6) : 473 - 480
  • [28] Prognostic Factors of Biologic Therapy in Pediatric IBD
    Buczynska, Anna
    Grzybowska-Chlebowczyk, Urszula
    CHILDREN-BASEL, 2022, 9 (10):
  • [29] Editorial: Microbiome in IBD: From Composition to Therapy
    Zhu, Ruixin
    He, Peijian
    Liu, Zhanju
    Liu, Ningning
    Miao, Yinglei
    Yu, Chenggong
    Zhu, Lixin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [30] There is still a place for optimised thiopurine therapy in IBD
    Crouwel, Femke
    Buiter, Hans J. C.
    de Boer, Nanne K. H.
    GUT, 2021, 70 (11) : 2207 - 2207